PRE-SUBMISSION MEETINGS BETWEEN FDA AND SPONSOR NEED NARROW FOCUS GIVEN DIFFICULTIES INHERENT IN DEVELOPING BINDING AGREEMENTS, BURLINGTON TELLS FDLI
This article was originally published in The Gray Sheet
Executive Summary
Pre-submission meetings between FDA and the sponsor of a premarket approval application or investigational device exemption will require a narrow focus in order to produce a written agreement between the two parties, Center for Devices and Radiological Health Director Bruce Burlington said Dec. 10 at a Food & Drug Law Institute meeting in Washington, D.C. During pre-PMA and pre-IDE meetings, Burlington cautioned, "it's going to be important that we focus on those issues on which agreement is going to be negotiated."
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.